CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...